Inside Life Sciences Issue 10: June 2020 Post Editor's Note Welcome to the Spring 2020 edition of Inside Life Sciences. News COVID-19: Pivoting to PPE manufacture – Key points to consider Acute shortages of personal protective equipment (PPE) in the UK have been widely reported. News COVID-19 and the Life Sciences Industry The life sciences industry has, understandably, been at the forefront of discussions regarding the global COVID-19 pandemic, with evolving pressures and challenges on governments, the healthcare system and drug developers. News Post-Brexit tariff regime begins to take shape This week the UK's Department for International Trade set out the details of the UK's new tariff regime, the UK Global Tariff (UKGT). News Inside Life Sciences – Patent and SPC Update Life Sciences businesses have, no doubt, become used to the twists and turns surrounding the Unified Patent Court and Unitary Patent regime. News High Court finds trade mark infringement through use of 'Merck' In a long-running dispute between Merck KGaA (Merck Global) and US companies Merck Sharp & Dohme Corporation and Merck & Co (together Merck US), the High Court has decided that various uses of 'Merck' in the UK by Merck US, amount to trade mark infringement. News Court of Appeal judgment in Flynn/Pfizer pricing case: where next for pharmaceutical pricing? In March 2020, the Court of Appeal handed down its judgment in Competition and Markets Authority v Flynn Pharma Ltd & Ors [2020] EWCA Civ 339. News "Pay-for-Delay" The Court of Justice of the European Union (the "CJEU") has given guidance on 'pay for delay' agreements for the first time in its recent decision in Generics (UK) v Competition and Markets Authority. News Patents Court rejects interim injunction in generic pharma dispute The Patents Court has refused an interim injunction sought by Neurim (and Flynn Pharma claiming as exclusive licensee) against Mylan in relation to its planned launch of a generic competitor product to Circadin. News Patents Court considers 'clearing the way' and disclosure of launch plans In Teva v Chiesi, the Patents Court has considered the extent to which a generic pharmaceutical company should clear the way to market before launch and the implications for an infringement counterclaim brought by a patentee based on a threat by the generic to infringe, in circumstances where the generic has not yet obtained a marketing authorisation. Previous Issues Prev Next Issue 13 Apr 2021 Issue 12 Nov 2020 Issue 11 Aug 2020 Issue 10 Jun 2020 Issue 9 Dec 2019 Issue 8 Jul 2019 Issue 7 Mar 2019 Issue 6 Nov 2018 Issue 5 Jul 2018 Issue 4 Mar 2018 Issue 3 Nov 2017 Share
News COVID-19: Pivoting to PPE manufacture – Key points to consider Acute shortages of personal protective equipment (PPE) in the UK have been widely reported.
News COVID-19 and the Life Sciences Industry The life sciences industry has, understandably, been at the forefront of discussions regarding the global COVID-19 pandemic, with evolving pressures and challenges on governments, the healthcare system and drug developers.
News Post-Brexit tariff regime begins to take shape This week the UK's Department for International Trade set out the details of the UK's new tariff regime, the UK Global Tariff (UKGT).
News Inside Life Sciences – Patent and SPC Update Life Sciences businesses have, no doubt, become used to the twists and turns surrounding the Unified Patent Court and Unitary Patent regime.
News High Court finds trade mark infringement through use of 'Merck' In a long-running dispute between Merck KGaA (Merck Global) and US companies Merck Sharp & Dohme Corporation and Merck & Co (together Merck US), the High Court has decided that various uses of 'Merck' in the UK by Merck US, amount to trade mark infringement.
News Court of Appeal judgment in Flynn/Pfizer pricing case: where next for pharmaceutical pricing? In March 2020, the Court of Appeal handed down its judgment in Competition and Markets Authority v Flynn Pharma Ltd & Ors [2020] EWCA Civ 339.
News "Pay-for-Delay" The Court of Justice of the European Union (the "CJEU") has given guidance on 'pay for delay' agreements for the first time in its recent decision in Generics (UK) v Competition and Markets Authority.
News Patents Court rejects interim injunction in generic pharma dispute The Patents Court has refused an interim injunction sought by Neurim (and Flynn Pharma claiming as exclusive licensee) against Mylan in relation to its planned launch of a generic competitor product to Circadin.
News Patents Court considers 'clearing the way' and disclosure of launch plans In Teva v Chiesi, the Patents Court has considered the extent to which a generic pharmaceutical company should clear the way to market before launch and the implications for an infringement counterclaim brought by a patentee based on a threat by the generic to infringe, in circumstances where the generic has not yet obtained a marketing authorisation.